1. Polk RE. Trends in fluoroquinolone (FG) prescribing in 35 US Hospitals and resistance forP. aeruginosa: a SCOPEMMIT report., Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001. American Society of Microbiology, Washington, DC. Abstract UL-1.
2. Iannini PB. Influence of fluoroquinolone usage of ciprofloxacin resistance ofPseudomonas aeruginosa. 3rdInternational Meeting on Antimicrobial Chemotherapy in Clinical Practice, Santa Margherita Ligure, October 16-19, 2003. Abstract #11.
3. Mohr J, Jones A, Tillotson GS. Impact of antimicrobial usage on susceptibility ofPseudomonas aeruginosaover an eight-year period at a community-based teaching hospital. 3rdInternational Meeting on Antimicrobial Chemotherapy in Clinical Practice, Santa Margherita Ligure, October 16-19, 2003. Abstract #32.
4. Dalhoff A, Heidtmann M, Obertegger S, Hesse D. Lack ofin vivoemergence of resistance against Bay 12-8039 inStaphylococcus aureusandStreptococcus pneumoniae. 8th International Conference on Infectious Diseases, Boston, MS, May 15-18, 1998. Abstract 124.
5. Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin (LEV) use and decreased susceptibility ofStreptococcus pneumoniae(SP): report from the arrest program., 3rd International Meeting on Antimicrobial Chemotherapy in Clinical Practice, Santa Margherita Ligure, October 16-19, 2003. Abstract #35.